Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2005-03-15
2005-03-15
Helms, Larry R. (Department: 1642)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S008100, C514S012200, C514S021800
Reexamination Certificate
active
06867180
ABSTRACT:
Methods for inhibiting endothelial cell growth and angiogenesis, and suppressing tumor growth using calreticulin, fragments of calreticulin and variants of calreticulin are provided. Such methods are useful for the treatment of cancer and diseases associated with unwanted angiogenesis, for example chronic retinal detachment.
REFERENCES:
patent: 5426097 (1995-06-01), Stern et al.
patent: 5591716 (1997-01-01), Siebert et al.
patent: 6596690 (2003-07-01), Tosato et al.
patent: 2140814 (1996-07-01), None
patent: WO 8909273 (1989-10-01), None
patent: WO 9513828 (1995-05-01), None
patent: WO 9623001 (1996-08-01), None
patent: WO 963664 (1996-11-01), None
patent: WO 9636643 (1996-11-01), None
patent: WO 0050080 (2000-08-01), None
Araya et al (2003, Eur Cytokine Netw. vol. 14, pp. 128-133, abstract only).*
Pike et al (1999, Blood, vol. 94, pp. 2461-2468).*
Dai et al.,Arteriosclerosis, Thrombosis and Vascular Biology,17(11):2359-2368, 1997 (abstract only); Medline abstract No. 1998073667, XP002133012.
Dedhar,TIBS,19:269-271, 1994.
Kishore et al.,Biochem. J.,322(2):543-550, 1997 (abstract only); Medline abstract No. 97218114, XP002133013.
Kuwabara et al.,J. Bio. Chem.,270(14):8179-8187, 1995.
Kwon et al.,Mol. Biol. of the Cell,11:1433-1443, 2000.
McDonnell et al.,J. Bio. Chem.,271(14):7891-7894, 1996.
Michalak et al.,Biochem. J.,285:681-692, 1992.
Nash et al.,Mol.&Cell Biochem.,135:71-78, 1994.
Pike et al.,Chemical Abstracts, 130(14), abstract No. 177891, 1999; &J. Experimental Medicine,188(12):2349-2356, 1998.
Pike et al,Blood,94(7):2461-2468, 1999.
Rokeach et al.,Protein Engineering,4(8):981-987, 1997.
Routsias et al.,Clinical and Experimental Immunology,91(3):437-441, 1993 (abstract only); Medline abstract No. 93185299, XP002133014.
Sontheimer et al.,J. Invest. Med.,43(4):362-370, 1995.
Stuart et al.,FEBS Letters,397:245-249, 1996.
Pike Sandra E.
Tosato Giovanna
Yao Lei
Helms Larry R.
Klarquist & Sparkman, LLP
The United States of America as represented by the Department of
Yu Misook
LandOfFree
Use of calreticulin and calreticulin fragments to inhibit... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of calreticulin and calreticulin fragments to inhibit..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of calreticulin and calreticulin fragments to inhibit... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3448990